Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05429268
Title Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Acronym firmMIND
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: senior | adult
Covered Countries TUR | ROU | POL | NOR | ISR | IRL | HUN | HRV | GBR | FIN | DNK | CZE | BGR


No variant requirements are available.